Chengdu HitGen and SPARC Enter into a DEL-Based Drug Discovery Collaboration Agreement

Chengdu HitGen Drug Discovery Co., Ltd. (hereinafter referred to as “HitGen”) recently announced a new drug R&D collaboration with Sun Pharmaceutical Advanced Research Centre (SPARC) of India (Reuters: SPRC.BO, Bloomberg: SPADV IN, National Stock Exchange of India: SPARC, Bombay Stock Exchange: 532870), aiming to discover novel structural compounds targeting SPARC’s areas of interest.Small Molecule Compounds. Under this agreement, HitGen Inc. will fully leverage its advanced technology platform, centered on the design, synthesis, and screening of DNA-encoded libraries (hereinafter referred to as “DEL”), to screen for new lead compounds for SPARC. Pursuant to the agreement, HitGen Inc. will receive an upfront payment and subsequent milestone payments.

Dr. Li Jin, Chairman and Chief Executive Officer of HitGen Inc., stated, “SPARC is an international pharmaceutical company headquartered in Mumbai, India. We are delighted to establish a collaboration with SPARC. This partnership further solidifies HitGen’s position in the rapidly evolving field of DNA-Encoded Library (DEL) technology. We will work closely with SPARC’s scientists to jointly discover novel lead compounds and advance their new drug development programs, aiming to address unmet medical needs.”

Anil Raghavan, CEO of SPARC, stated, “We believe that combining HitGen’s unique DNA-encoded compound library design, synthesis, and screening technology platform with SPARC’s R&D capabilities will inevitably accelerate the progress of SPARC’s new drug development pipeline. We look forward to collaborating with HitGen and are committed to bringing more valuable new medicines to patients.”

About HitGen

HitGen Inc. is a rapidly growing biotechnology company engaged in new drug research and development, headquartered in Chengdu, China, with a subsidiary in the United States. HitGen has established a DNA-centric small-molecule drug discovery platform, namely the DNA-Encoded Compound Library (DEL) design, synthesis, and screening technology platform. To date, the company has synthesized nearly 400 billion structurally novel, diverse, and drug-like DNA-encoded compounds based on hundreds of different scaffold structures. Multiple cases have demonstrated its capability to screen hit compounds against both known and emerging targets. HitGen’s business spans North America, Europe, Asia, and Africa. The company has established collaborations with numerous international pharmaceutical giants, biotechnology firms, chemical companies, foundations, and research institutions, dedicated to the discovery and development of new drugs and agrochemical solutions.

About SPARC (CIN: L73100GJ2006PLC047837)

SPARC is an international pharmaceutical company dedicated to the continuous development of new therapies, providing better medical care for patients worldwide. SPARC aims to reduce production costs, improve operational efficiency, and advance patient treatment regimens.BioonBioon.com）

Editor's PickMeeting2019 DNA-Encoded Compound Library (Shanghai) Symposium

http://meeting.bioon.com/2019DEL?__token=liaodefeng